Liu Kexuan, Huang Lei, Qi Shuangyan, Liu Shuchen, Xie Wangni, Du Liuyi, Cui Jing, Zhang Xu, Zhang Boya, Liu Lijun, Li Daowei, Sun Hongchen
Jilin Provincial Key Laboratory of Oral Biomedical Engineering, School and Hospital of Stomatology, Jilin University, Changchun, 130021, P. R. China.
Adv Healthc Mater. 2023 May;12(12):e2203085. doi: 10.1002/adhm.202203085. Epub 2023 Feb 3.
Ferroptosis is a non-apoptotic programmed cell death caused by the accumulation of lipid peroxide. System Xc-/glutathione peroxidase 4 (GPX4) axis and iron axis are two main pathways regulating ferroptosis. Simultaneously, multiple pathways are also involved in the ferroptosis regulation. Ferroptosis is an intense area of the current study. With the improvement of the regulatory mechanisms that underlie ferroptosis, a variety of drugs associated with ferroptosis have been discovered and developed for cancer therapy. Among them, traditional drugs were developed initially. Small molecule compounds that regulate ferroptosis signaling pathway and iron complexes that promote the Fenton reaction have become important drugs for inducing ferroptosis. In recent years, the emerging development of nanotechnology has promoted the research of ferroptosis nanodrugs. Iron-based nanomaterials are extensively tested as ferroptosis-inducing agents. Furthermore, nanoscale drug delivery systems offer a suitable scaffold for traditional drug therapies. Traditional drugs and nanodrugs are complementary, each with their own strengths and limitations. This review describes the latest studies on the regulation of ferroptosis in tumor cells and focuses on the entanglement between traditional drugs and nanodrugs. To conclude, the challenges and perspectives in this field are put forward.
铁死亡是一种由脂质过氧化物积累引起的非凋亡性程序性细胞死亡。系统Xc-/谷胱甘肽过氧化物酶4(GPX4)轴和铁轴是调节铁死亡的两条主要途径。同时,多种途径也参与铁死亡调节。铁死亡是当前研究的一个热点领域。随着铁死亡潜在调节机制的不断完善,已发现并开发了多种与铁死亡相关的药物用于癌症治疗。其中,传统药物是最早开发的。调节铁死亡信号通路的小分子化合物和促进芬顿反应的铁络合物已成为诱导铁死亡的重要药物。近年来,纳米技术的新兴发展推动了铁死亡纳米药物的研究。铁基纳米材料作为铁死亡诱导剂得到了广泛测试。此外,纳米级药物递送系统为传统药物治疗提供了合适的支架。传统药物和纳米药物相互补充,各有优缺点。本文综述了肿瘤细胞中铁死亡调节的最新研究,并重点关注传统药物与纳米药物之间的纠结。最后,提出了该领域的挑战和展望。